OptraSCAN, in which Molbio Diagnostics holds a majority stake, has received US FDA 510(k) clearance for its OptraSCAN System, supporting HER2 expression assessment in breast cancer diagnostics. Dr Reena Nakra, Chief Scientific Officer, Dr Lal PathLabs, called it an encouraging step for digital pathology adoption worldwide.